Journal
PARASITE
Volume 18, Issue 3, Pages 207-214Publisher
EDP SCIENCES S A
DOI: 10.1051/parasite/2011183207
Keywords
malaria; bioorganometallics; drug candidate; ferroquine; mechanism of action; resistance
Categories
Funding
- Pierre Fabre Medicament
- Sanofi-Aventis
- Wellcome Trust of Great Britain
Ask authors/readers for more resources
Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
